Tenderwize
Retour à la recherche

Pharmaceutical rebate agreements with accession option

BARMER Beschaffung und Vergabe·Wuppertal, Germany·Deadline Nov 01, 2027 · 429 days left·Open·Supplies·Framework
Inscrivez-vous pour sauvegarder
Structured notice only
Titre original de l'avis

Germany – Pharmaceutical products – Arzneimittelrabattverträge mit Beitrittsoption

20/100

Score d'opportunité

Needs reviewMedium complexity
SuppliesFrameworkOpen
Pourquoi ce score ?

Opportunité

20 / 100

Complexité

45 / 100

Facteurs de risque

No estimated value, award criteria, or eligibility criteria are provided. This makes it impossible to assess the tender...

The notice states it is not a public procurement under EU Directive 2014/24/EU, yet it uses the open procedure label. T...

No procurement documents available

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Framework procurement
  • Supplies contract
  • 2 lots
  • Duration until Dec 2027
  • Supply of pharmaceutical products containing Aflibercept 40 mg/ml in two forms: vials (Durchstechflaschen) and pre-filled syringes (Fertigspritzen).
  • Framework agreement with accession option (Beitrittsoption) allowing additional parties to join.
Afficher le résumé complet

This is a German framework agreement with accession option for pharmaceutical products (Aflibercept) issued by BARMER Beschaffung und Vergabe. It consists of two lots: one for vials (40 mg/ml) and one for pre-filled syringes (40 mg/ml). The notice explicitly states it is not a public procurement under EU directives, but uses an open procedure format. No estimated values, award criteria, or eligibility criteria are provided. The submission deadline is November 1, 2027, with a two-year contract period starting December 1, 2025. The buyer is a health insurance body. The tender is available only electronically via the buyer's platform. Documents were not analyzed beyond the XML notice.

Risques

No estimated value, award criteria, or eligibility criteria are provided. This makes it impossible to assess the tender...

The notice states it is not a public procurement under EU Directive 2014/24/EU, yet it uses the open procedure label. T...

No procurement documents available

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Maximum of 2 lots can be awarded to one tenderer (MaximumLotsAwardedNumeric: 2).
  • Variants are not allowed.

Administrative

  • Tenders must be submitted electronically via the buyer's platform (Ouvrir le portail).

Les exigences peuvent être incomplètes.

Acheteur

Localisation

Wuppertal, DEU

Identifiant

992-80322-57

Activité

Health

Lots (2)

LOT-0001

Aflibercept (Vials 40 mg/ml)

Supply of medicinal products containing Aflibercept in vial form (40 mg/ml). Framework agreement with accession option.

SuppliesFrameworkEU fundedElectronic submission

Localisation

Wuppertal, Germany

Durée

Nov 2025 - Dec 2027

Catégorie

Pharmaceutical products

Date limite

Deadline Nov 01, 2027

LOT-0002

Aflibercept (Pre-filled Syringes 40 mg/ml)

Supply of medicinal products containing Aflibercept in pre-filled syringe form (40 mg/ml). Framework agreement with accession option.

SuppliesFrameworkEU fundedElectronic submission

Localisation

Wuppertal, Germany

Durée

Nov 2025 - Dec 2027

Catégorie

Pharmaceutical products

Date limite

Deadline Nov 01, 2027

Détails de la procédure

Date de publication
20 Oct 2025
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
692194-2025

Documents (1)

Portail de soumission 1

Appels d'offres similaires

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30